- Report
- May 2026
- 150 Pages
Spain
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
Thailand
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
Turkey
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
United Kingdom
From €4411EUR$4,850USD£3,779GBP
- Report
- October 2022
- 286 Pages
Global
From €2274EUR$2,500USD£1,948GBP
- Drug Pipelines
- March 2021
Global
From €1819EUR$2,000USD£1,558GBP
- Drug Pipelines
- October 2020
- 375 Pages
Global
From €1819EUR$2,000USD£1,558GBP
- Report
- December 2022
- 35 Pages
Global
From €1819EUR$2,000USD£1,558GBP
- Report
- December 2022
- 37 Pages
Global
From €1819EUR$2,000USD£1,558GBP
- Report
- October 2022
- 142 Pages
Global
From €1819EUR$2,000USD£1,558GBP
- Report
- July 2022
- 100 Pages
Global
From €3183EUR$3,500USD£2,727GBP
- Report
- January 2024
- 120 Pages
Global
From €3500EUR$4,123USD£3,104GBP
- Report
- March 2022
- 90 Pages
Global
From €3500EUR$4,123USD£3,104GBP

The Metabolic Disorder Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. It includes drugs used to treat metabolic disorders such as diabetes, obesity, and hyperlipidemia. These drugs are used to regulate the body's metabolism, which is the process of converting food into energy. Common drugs used to treat metabolic disorders include insulin, sulfonylureas, biguanides, thiazolidinediones, and GLP-1 agonists. These drugs are used to control blood sugar levels, reduce cholesterol, and promote weight loss.
The Metabolic Disorder Drug market is highly competitive, with many companies offering a variety of drugs to treat metabolic disorders. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. Other companies in the market include Boehringer Ingelheim, Takeda, and Pfizer. Show Less Read more